Zacks Research Issues Pessimistic Forecast for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Zacks Research dropped their Q3 2026 earnings estimates for shares of Puma Biotechnology in a report released on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, down from their previous estimate of $0.08. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2027 earnings at $0.02 EPS.

Several other equities research analysts have also recently issued reports on PBYI. TD Cowen raised their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 21st. Finally, Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Puma Biotechnology Trading Up 2.6%

Shares of NASDAQ:PBYI opened at $9.35 on Wednesday. The stock’s 50-day moving average price is $8.43 and its two-hundred day moving average price is $7.47. Puma Biotechnology has a 12-month low of $4.30 and a 12-month high of $9.59. The firm has a market cap of $482.65 million, a price-to-earnings ratio of 17.98 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to analysts’ expectations of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.

Insider Buying and Selling at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 44,058 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $8.26, for a total value of $363,919.08. Following the transaction, the chief executive officer owned 7,261,671 shares in the company, valued at approximately $59,981,402.46. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian Senderowicz sold 27,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.20, for a total transaction of $194,400.00. Following the sale, the director owned 27,000 shares of the company’s stock, valued at approximately $194,400. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 132,028 shares of company stock worth $1,006,711. Company insiders own 22.20% of the company’s stock.

Institutional Trading of Puma Biotechnology

Several large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its stake in shares of Puma Biotechnology by 244.5% during the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,066 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Puma Biotechnology during the second quarter worth $35,000. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology during the second quarter worth $36,000. California State Teachers Retirement System boosted its stake in shares of Puma Biotechnology by 110.2% in the second quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 2,568 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.